Nucleoside metabolic inhibitor — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the nucleoside metabolic inhibitor class. 27 active patents protecting 3 drugs. First major cliff: 2030. Daily refresh.

3
Drugs in class
27
Active US patents
60/100
Avg vulnerability
—
Annual revenue covered

Originators

Accord Hlthcare 15 patents Bristol-Myers Squibb 6 patents

Cliff calendar — next 15 years

2
28
4
29
5
30
1
32
10
33
2
34
1
40
2
41

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Gemzar
Gemcitabine Hydrochloride
 Accord Hlthcare 15 48 — 2030-06-28
Vidaza
azacitidine
 Bristol-Myers Squibb 6 73 — 2029-05-14
CEDAZURIDINE — 6 58 — 2028-10-16

Most attackable patents

Patent Drug Type Vuln Expiry
12053482 Vidaza method of use 88 2029-05-14
12053482 Vidaza method of use 88 2029-05-14
8618075 CEDAZURIDINE method of use 75 2028-10-16
12239653 CEDAZURIDINE method of use 75 2041-02-24
8846628 Vidaza method of use 68 2030-06-03
8846628 Vidaza method of use 68 2030-06-03
8268800 CEDAZURIDINE method of use 68 2030-08-22
11571436 Vidaza formulation 63 2029-05-14
11571436 Vidaza formulation 63 2029-05-14
12403086 Gemzar formulation 61 2030-06-28

Strongest defences

Patent Drug Type Vuln Expiry
9567363 CEDAZURIDINE composition of matter 17 2028-10-16
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01

Related